Japan multicenter prospective study: FDG-PET/CT as imaging biomarker to evaluate the response of Axitinib for Sunitinib failed metastatic renal cell carcinoma patients.

Trial Profile

Japan multicenter prospective study: FDG-PET/CT as imaging biomarker to evaluate the response of Axitinib for Sunitinib failed metastatic renal cell carcinoma patients.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Jan 2014

At a glance

  • Drugs Axitinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 19 Jan 2014 According to University Hospital Medical Information Network-Japan record, status changed from not yet recruiting to recruiting.
    • 16 Dec 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top